Background: Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's lymphoma (HL). We studied a high-dose chemotherapy regimen based on thiotepa, etoposide and carboplatin (TECA). Methods: Fifty-eight patients with advanced HL were treated with thiotepa, etoposide and carbo platin for transplant induction. Results: The overall response rate was 79.3% (39 CR: 67.2%; and 7 PR: 12.1%); 12 patients (20.1%) were non-responders. The 5-year overall survival rate was 77.6%; five initially responder patients relapsed within the first 5 years of follow-up and underwent salvage therapy. Conclusion: The TECA conditioning regimen for ASCT in HL results in a good anti-HL effect, positive response to treatment and high 5-y...
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and predniso...
Patients with chemosensitive aggressive non-Hodgkin lymphoma (NHL) could benefit from high-dose chem...
Purpose of review The treatment of high-risk classic Hodgkin lymphoma (cHL) patients remains challen...
Background: Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's...
AbstractBackground: Autologous stem cell transplantation (ASCT) generally provides good results in H...
High-dose chemotherapy conditioning regimens followed by autologous stem cell transplantation genera...
Purpose: As well as standard chemotherapy, autologous stem cell transplantation (ASCT) is also seen ...
To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should...
Trials have demonstrated that high-dose escalation followed by autologous transplantation can promot...
Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among whic...
We report results of a thiotepa-based conditioning in haploidentical stem cell transplantation (hapl...
BACKGROUND: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard...
We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemo...
Background/aim High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has be...
Evaluation of: Cocorocchio E, Peccatori F, Vanazzi A et al. High-dose chemotherapy in relapsed or re...
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and predniso...
Patients with chemosensitive aggressive non-Hodgkin lymphoma (NHL) could benefit from high-dose chem...
Purpose of review The treatment of high-risk classic Hodgkin lymphoma (cHL) patients remains challen...
Background: Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's...
AbstractBackground: Autologous stem cell transplantation (ASCT) generally provides good results in H...
High-dose chemotherapy conditioning regimens followed by autologous stem cell transplantation genera...
Purpose: As well as standard chemotherapy, autologous stem cell transplantation (ASCT) is also seen ...
To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should...
Trials have demonstrated that high-dose escalation followed by autologous transplantation can promot...
Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among whic...
We report results of a thiotepa-based conditioning in haploidentical stem cell transplantation (hapl...
BACKGROUND: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard...
We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemo...
Background/aim High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has be...
Evaluation of: Cocorocchio E, Peccatori F, Vanazzi A et al. High-dose chemotherapy in relapsed or re...
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and predniso...
Patients with chemosensitive aggressive non-Hodgkin lymphoma (NHL) could benefit from high-dose chem...
Purpose of review The treatment of high-risk classic Hodgkin lymphoma (cHL) patients remains challen...